Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 50% Gains Investing -- Ignore unavailable to you. Want to Upgrade?

To: Dale Baker who wrote (13881)	1/3/2000 5:33:00 AM
From: GeoDude	Read Replies (1) \| Respond to of 118717

For the medium term investor: check AKRN. Profitable pharma manufacturer and inked a deal with PHGN to manufacture and distribute a soon to be FDA approved drug that helps cure a type of eye cancer. The drug has a $500M+/year market (check PHGN to verify), so ARKN should indirectly benefit. This is my translation of the biotech gurus talk. Since ARKN has a low low market cap, little downside. They also are planning on expansion and acquisition so the core business will add value too. I see an easy double sometime in '00 and $20/share by end '00. Disclosure: I bought some at $4.5 last week. And it is a value stock. Not a daytrading toy. Enjoy the new year, LIA